Some current practices in designing and analyzing short-term trials in asthma are examined from a statistical point of view. The trials considered consist principally of crossover trials to examine dose response, onset of action, duration of action, and protective effects of treatments or bioequivalence. It is concluded that a proper appreciation of the way in which causality may be investigated in clinical trials would lead to an improvement in design and analysis of short-term trials in asthma.
GrizzleG. The Two-Period Change-over Design and its use in Clinical Trials. Biometrics. 1965;21: 467–480.
5.
PSI Working Party on Cross-over Studies.PSI. 1980.
6.
FreemanPR. The Performance of the Two-Stage Analysis of Two-Treatment, Two-Period Crossover Trials. Stat Med.1989;9: 1421–1432.
7.
SennSJ. Problems with the Two Stage Analysis of Crossover Trials. Br J Clin Pharm.1991;32: 133.
8.
SennSJ. Cross-over Trials in Clinical Research. Chichester, England: Wiley; 1993.
9.
MartinRJPakJ. Overnight Theophylline Concentrations and Effects on Sleep and Lung Function in Chronic Obstructive Pulmonary Disease. Am Rev Respir Dis. 1992;145: 540–544.
10.
JonesBKenwardM. Design and Analysis of Cross-Over Trials. London: Chapman and Hall; 1989.
11.
FleissJL. Letter to the Editor. Biometrics. 1986;42: 449–450.
12.
FleissJL. A Critique of Recent Research on the two-Treatment Crossover Design. Cont Clin Trials. 1989;10: 237–243.
13.
SennSJ. Is the Simple Carry-over Model Useful?Stat Med.1992:11;715–726.
CoxDRFitzpatrickRFletcherAEGoreSMSpiegelhalterDJJonesDRI. Quality of Life Assessment: Can We Keep it Simple?J Royal Stat Soc A. 1992;155:353–393.
16.
GayrardPOrehekJ. Mesure d'un Effect Bronchodilateur par le VEMS: Comment l'Exprimer?Rev Mal Resp. 1984;1:81–84.
17.
GrandordyBMThomasVde LautreDMarsacJ. Cumulative Dose-Response Curves for Assessing Combined Effects of Salbutamol and Ipratropium Bromide in Chronic Asthma. Eur Resp J.1988;1: 531–535.
18.
KronmalR. 'Spurious Correlation and the Fallacy of the Ratio Standard Revisited.' (Private communication: to be published.).
19.
SpeelbergBVerhoeffNPLGvan den BergNJOosthoekCHAvan HerwaardenCLABruijn-zeelPLB. Nedocromil Sodium Inhibits the Early and Late Asthmatic Response to Exercise. Eur Respir J.1992;5: 430–437.
20.
GuyattGHTownsendMNogradiSPugsleySOKellerJLNewhouseMT. Acute Response to Bronchodilator. Arch Intern Med.1988;148: 1949–1952.
TempleR. Government View of Clinical Trials. Drug Inf J.1982;16: 10–17.
23.
RubinDB. Practical Implications of Modes of Statistical Inference for Causal Effects and the Critical Role of the Assignment Mechanism. Biometrics. 1991;47: 1213–1234.
24.
McGilverayIJ. Bioavailability testing of medicinal products and harmonization of international testing requirements and standards: the Canadian perspective. Drug Inf J.1992;26: 365–369.
25.
O'NeillRTChenCW. A Statistical Procedure Useful in Evaluating Time of Onset and Termination of Response in Clinical Trials. Biometrics. 1978;34: 411–420.
26.
RubinDB. Comment on Randomization Analysis of Experimental Data: The Fisher Randomization Test (by Basu). J Am Stat Ass. 1980;75: 591–593.
LeuenbergerPGebre-MichelI. Preventive Effect of Formoterol in Methacholine-Induced Bronchoconstriction. In: DaviesR, ed. Formoterol in Asthma—Clinical Profile of a new Long-Acting Inhaled β-Agonist. Toronto, Canada: Hogrefe and Huber; 1989.
29.
CartierAThomsonNCFrithPARobertsRHargreaveFE. Allergen-Induced Increase in Bronchial Responsiveness to Histamine: Relationship to the Late Asthmatic Response and Change in Airway Caliber. J Allergy Clin Immunol. 1982;70(3):170–177.
